n-acetylmannosamine
Small moleculeexperimental
N-Acetylmannosamine is a hexosamine monosaccharide. It is a neutral, stable naturally occurring compound. N-Acetylmannosamine is also known as N-Acetyl-D-mannosamine monohydrate,, N-Acetyl-D-mannosamine which can be abbreviated to ManNAc or, less commonly, NAM). ManNAc is the first committed biological precursor of N-acetylneuraminic acid. Sialic acids are the negatively charged, terminal monosaccharides of carbohydrate chains that are attached to glycoproteins and glycolipids (glycans). — Wikipedia
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 7, 2012 (NCT01634750)
Timeline
Indications
Mechanism of action
- Unspecified targetSupplementation
supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O- Mol. weight
- 221.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaN-Acetylmannosamine ↗
- ChEMBLCHEMBL1231391 ↗
Also known as
- mannac
- mannac
- n-acetylmannosamine
- n-acetylmannosamine
- n-acetylmannosamine
- n-acetyl-mannosamine
- n-acetyl-mannosamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06664814 | Phase 2 | Nov 17, 2024 | National Human Genome Research Institute (NHGRI) |
| NCT04231266 | Phase 2 | Feb 1, 2020 | Harvard University, Leadiant Biosciences, Inc., National Human Genome Research Institute (NHGRI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT02639260 | Phase 1 | Dec 10, 2015 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT02346461 | Phase 1/Phase 2 (Phase 2) | Jan 14, 2015 | National Center for Advancing Translational Science (NCATS), National Human Genome Research Institute (NHGRI) |
| NCT01634750 | Phase 1 | Sep 7, 2012 | National Center for Advancing Translational Science (NCATS), National Human Genome Research Institute (NHGRI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Human Genome Research Institute (NHGRI) | Government | 4 | 4 | 2 | 2012 |
| National Center for Advancing Translational Science (NCATS) | Government | 2 | 0 | 2 | 2012 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Leadiant Biosciences, Inc. | For profit | 1 | 0 | 1 | 2020 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 0 | 1 | 2020 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2015 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1